Structural variations of the cell wall precursor lipid II in Gram-positive bacteria - Impact on binding and efficacy of antimicrobial peptides

Biochimica et Biophysica Acta - Biomembranes

Volumn 1848, Issue 11, 2015, Pages 3062-3071

  Münch, Daniela ^a   Sahl, Hans Georg ^b  

^a AiCuris GmbH   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

AMP; Antimicrobial peptide; Cell wall; Lipid II; Peptidoglycan

Indexed keywords

DALBAVANCIN; DAPTOMYCIN; DEFENSIN; ENDURACIDIN; GLUTAMIC ACID; GLYCAN; GRAMICIDIN S; LANTIBIOTIC; LIPID II; MEMBRANE LIPID; MERSACIDIN; ORITAVANCIN; PEPTIDOGLYCAN; PLECTASIN; POLYMYXIN B; POLYPEPTIDE ANTIBIOTIC AGENT; RAMOPLANIN; SYNTHETIC PEPTIDE; TELAVANCIN; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; MURAMYL-NAC-(PENTAPEPTIDE)PYROPHOSPHORYL-UNDECAPRENOL; PROTEIN BINDING; URIDINE DIPHOSPHATE N ACETYLMURAMIC ACID;

AMIDATION; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACILLI; BACTERIAL GENE; BACTERIAL PHENOMENA AND FUNCTIONS; BACTERIAL STRAIN; BINDING AFFINITY; CHEMICAL REACTION; CROSS LINKING; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENTEROCOCCUS FAECALIS; FEMC GENE; GLYCOSYLATION; GRAM POSITIVE BACTERIUM; HUMAN; HYDROPHOBICITY; IMMUNE RESPONSE; INNATE IMMUNITY; MATHEMATICAL MODEL; MYCOBACTERIUM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; SPECIES COMPOSITION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TRANSPEPTIDATION; ANALOGS AND DERIVATIVES; ANIMAL; CELL WALL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; GRAM-POSITIVE BACTERIAL INFECTIONS; HOST PATHOGEN INTERACTION; METABOLISM; MICROBIAL VIABILITY; MICROBIOLOGY; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CELL WALL; DRUG RESISTANCE, BACTERIAL; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HOST-PATHOGEN INTERACTIONS; HUMANS; MICROBIAL VIABILITY; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN BINDING; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; URIDINE DIPHOSPHATE N-ACETYLMURAMIC ACID;

EID: 84943817577     PISSN: 00052736     EISSN: 18792642     Source Type: Journal    
DOI: 10.1016/j.bbamem.2015.04.014     Document Type: Review

References (122)

1. J.V. Höltje Growth of the stress-bearing and shape-maintaining murein sacculus of Escherichia coli Microbiol. Mol. Biol. Rev. 62 1998 181 203
2. D.W. Adams, and J. Errington Bacterial cell division: assembly, maintenance and disassembly of the Z ring Nat. Rev. Microbiol. 7 9 2009 642 653
3. D. Patin, A. Boniface, A. Kovac, M. Herve, S. Dementin, and et al. Purification and biochemical characterization of Mur-ligases from Staphylococcus aureus Biochimie 92 2010 1793 1800
4. H.J. van Heijenoort Recent advances in the formation of the bacterial peptidoglycan monomer unit Nat. Prod. Rep. 18 2001 503 519
5. T.D. Bugg, and C.T. Walsh Intracellular steps of bacterial cell wall peptidoglycan biosynthesis: enzymology, antibiotics, and antibiotic resistance Nat. Prod. Rep. 9 1992 199 215
6. C.A. Smith Structure, function and dynamics in the Mur-family of bacterial cell wall ligases J. Mol. Biol. 362 2006 640 655
7. A. Bouhss, A.E. Trunkfield, T.D. Bugg, and D. Mengin-Lecreulx The biosynthesis of peptidoglycan lipid-linked intermediates FEMS Microbiol. Rev. 32 2008 208 233
8. H.J. van Heijenoort Lipid intermediates in the biosynthesis of bacterial peptidoglycan Microbiol. Mol. Biol. Rev. 71 2007 620 635
9. T. Mohammadi, V. van Dam, R. Sijbrandi, T. Vernet, A. Zapun, and et al. Identification of FtsW as a transporter of lipid-linked cell wall precursors across the membrane EMBO J. 30 2011 1425 1432
10. H.J. Van Heijenoort Formation of the glycan chains in the synthesis of bacterial peptidoglycan Glycobiology 11 2001 25R 36R
11. D.J. Scheffers, and M.G. Pinho Bacterial cell wall synthesis: new insights from localization studies Microbiol. Mol. Biol. Rev. 69 2005 585 607
12. P.G. Arnison, and et al. Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature Nat. Prod. Rep. 30 2013 108 160
13. H.L. Condurso, and S.D. Bruner Structure and noncanonical chemistry of nonribosomal peptide biosynthetic machinery Nat. Prod. Rep. 29 10 2012 1099 1110
14. M. Zasloff Antimicrobial peptides of multicellular organisms Nature 6870 2002 389 395
15. Miriam Wilmes, Bruno P.A. Cammue, Hans-Georg Sahl, and et al. Antibiotic activities of host defense peptides: more to it than lipid bilayer perturbation Nat. Prod. Rep. 28 8 2011 1350 1358
16. T. Schneider, and H.G. Sahl An oldie but a goodie - cell wall biosynthesis as antibiotic target pathway Int. J. Microbiol. 300 2010 161 169
17. Yount, and Yeaman Peptide antimicrobials: cell wall as a bacterial target Ann. N. Y. Acad. Sci. 1277 2013 127 138
18. T. Schneider, T. Kruse, R. Wimmer, I. Wiedemann, V. Sass, and et al. Plectasin, a fungal defensin, targets the bacterial cell wall precursor Lipid II Science 328 2010 1168 1172
19. Oeemig Js, C. Lynggaard, D.H. Knudsen, F.T. Hansen, K.D. Nørgaard, T. Schneider, B.S. Vad, D.H. Sandvang, L.A. Nielsen, S. Neve, H.H. Kristensen, H.G. Sahl, D.E. Otzen, and R. Wimmer Eurocin, a new fungal defensin: structure, lipid binding, and its mode of action J. Biol. Chem. 287 50 2012 42361 42372
20. V. Sass, T. Schneider, M. Wilmes, C. Korner, A. Tossi, N. Novikova, O. Shamova, and H.G. Sahl Human beta-defensin 3 inhibits cell wall biosynthesis in Staphylococci Infect. Immun. 78 2010 2793 2800
21. E. de Leeuw, C.Q. Li, P.Y. Zeng, C. Li, M. Diepeveen-de Buin, W.Y. Lu, E. Breukink, and W.Y. Lu FEBS Lett. 584 2010 1543 1548
22. G. Bierbaum, and H.G. Sahl Lantibiotics: mode of action, biosynthesis and bioengineering Curr. Pharm. Biotechnol. 10 1 2009 2 18
23. L. Rogers The inhibiting effect of Streptococcus lactis on Lactobacillus bulgaricus J. Bacteriol. 16 1928 321
24. I. Wiedemann, E. Breukink, C. van Kraaij, O.P. Kuipers, G. Bierbaum, B. de Kruijff, and H.G. Sahl Specific binding of nisin to the peptidoglycan precursor Lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity J. Biol. Chem. 276 3 2001 1772 1779
25. E. Breukink, I. Wiedemann, C. Kraaij, O.P. Kuipers, H.G. Sahl, and B. De Kruijff Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic Science 286 1999 2361
26. H. Brötz, M. Josten, I. Wiedemann, U. Schneider, F. Götz, G. Bierbaum, and H.G. Sahl Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics Mol. Microbiol. 30 1998 317 327
27. S.T.D. Hsu, E. Breukink, E. Tischenko, M.A.G. Lutters, B. De Kruijff, R. Kaptein, A.M.J.J. Bonvin, and N.A.J. Van Nuland The nisin-lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics Nat. Struct. Mol. Biol. 11 2004 963 967
28. E. Ruhr, and H.G. Sahl Mode of action of the peptide antibiotic nisin and influence on the membrane potential of whole cells and on cytoplasmic and artificial membrane vesicles Antimicrob. Agents Chemother. 27 1985 841
29. H.G. Sahl, and H. Brandis Efflux of low-Mr substances from the cytoplasm of sensitive cells caused by the staphylococcin-like agent Pep5 FEMS Microbiol. Lett. 16 1983 75 79
30. H.G. Sahl, M. Kordel, and R. Benz Voltage-dependent depolarization of bacterial membranes and artificial lipid bilayers by the peptide antibiotic nisin Arch. Microbiol. 149 1987 120 124
31. J.M. Willey, and W.A. Van der Donk Lantibiotics: peptides of diverse structure and function Annu. Rev. Microbiol. 61 2007 477 501
32. H. Brötz, G. Bierbaum, P.E. Reynolds, and H.G. Sahl The lantibiotic mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation Eur. J. Biochem. 246 1997 193 199
33. R. Finking, and M.A. Marahiel Biosynthesis of nonribosomal peptides Annu. Rev. Microbiol. 58 2004 453 488
34. B.A. Johnson, H. Anker, and F.L. Meleney Bacitracin: A new antibiotic produced by a member of the B. subtilis group Science 102 2650 1945 376 377
35. N.J. Economou, S. Cocklin, and P.J. Loll High-resolution crystal structure reveals molecular details of target recognition by bacitracin Proc. Natl. Acad. Sci. U. S. A. 110 35 2013 14207 14212
36. X. Fang, K. Tiyanont, Y. Zhang, J. Wanner, D. Boger, and S. Walker The mechanism of action of ramoplanin and enduracidin Mol. Biosyst. 2 1 2006 69 76
37. M.H. McCormick, W.M. Stark, G.E. Pittenger, R.C. Pittenger, and J.M. McGuire Vancomycin, a new antibiotic. Chemical and biological properties Antibiot. Annu. 1955-1956 1956 606 611
38. T.I. Nicas, and N.E. Allen R. Nagarajan, Glycopeptide Antibiotics 1994 Marcel Dekker New York 219 241
39. P.E. Reynolds Structure, biochemistry and mechanism of action of glycopeptide antibiotics Eur. J. Clin. Microbiol. Infect. Dis. 8 1989 943 950
40. H.R. Perkins, and M. Nieto The chemical basis for the action of the vancomycin group of antibiotics Ann. N. Y. Acad. Sci. 235 1974 348 363
41. Breukink, and de Kruijff Lipid II as a target for antibiotics Nat. Rev. Drug Discov. 5 4 2006 321 332
42. L.T. Nguyen, E.F. Haney, and H.J. Vogel The expanding scope of antimicrobial peptide structures and their modes of action Trends Biotechnol. 29 9 2011 464 472 10.1016/j.tibtech
43. P.J. Knerr, and W.A. van der Donk Discovery, biosynthesis, and engineering of lantipeptides Annu. Rev. Biochem. 81 2012 479 505 10.1146/annurev-biochem-060110-113521
44. Z. Sun, J. Zhong, X. Liang, J. Liu, X. Chen, and L. Huan Novel mechanism for nisin resistance via proteolytic degradation of nisin by the nisin resistance protein NSR Antimicrob. Agents Chemother. 53 5 2009 1964 1973 10.1128/AAC
45. M. Otto Bacterial evasion of antimicrobial peptides by biofilm formation Curr. Top. Microbiol. Immunol. 306 2006 251 258
46. M. Perego, P. Glaser, A. Minutello, M.A. Strauch, K. Leopold, and W. Fischer Incorporation of d-alanine into lipoteichoic acid and wall teichoic acid in Bacillus subtilis. Identification of genes and regulation J. Biol. Chem. 270 26 1995 15598 15606
47. Neuhaus, and Baddiley A continuum of anionic charge: structures and functions of d-alanyl-teichoic acids in Gram-positive bacteria Microbiol. Mol. Biol. Rev. 67 4 2003 686 723
48. McBride, and Sonenshein The dlt operon confers resistance to cationic antimicrobial peptides in Clostridium difficile Microbiology 157 Pt 5 2011 1457 1465 10.1099/mic.0.045997-0
49. N.T. Reichmann, C.P. Cassona, and A. Gründling Revised mechanism of d-alanine incorporation into cell wall polymers in Gram-positive bacteria Microbiology 159 Pt 9 2013 1868 1877 10.1099/mic
50. A. Peschel, and L.V. Collins Staphylococcal resistance to antimicrobial peptides of mammalian and bacterial origin Peptides 22 10 2001 1651 1659.
51. Y. Oku, K. Kurokawa, N. Ichihashi, and K. Sekimizu Characterization of the Staphylococcus aureus mprF gene, involved in lysinylation of phosphatidylglycerol Microbiology 150 Pt 1 2004 45 51
52. J. Andrä, T. Goldmann, C.M. Ernst, A. Peschel, and T. Gutsmann Multiple peptide resistance factor (MprF)-mediated resistance of Staphylococcus aureus against antimicrobial peptides coincides with a modulated peptide interaction with artificial membranes comprising lysyl-phosphatidylglycerol J. Biol. Chem. 286 21 2011 18692 18700 10.1074/jbc.M111.226886
53. B.D. Needham, and M.S. Trent Fortifying the barrier: the impact of lipid A remodelling on bacterial pathogenesis Na Rev Microbiol 11 7 2013 467 481 10.1038/nrmicro3047
54. A.L. Cheung, A.S. Bayer, M.R. Yeaman, Y.Q. Xiong, A.J. Waring, G. Memmi, N. Donegan, S. Chaili, and S.J. Yang Site-specific mutation of the sensor kinase GraS in Staphylococcus aureus alters the adaptive response to distinct cationic antimicrobial peptides Infect. Immun. 82 12 2014 5336 5345 10.1128/IAI.02480-14
55. Z.D. Dalebroux, and S.I. Miller Salmonellae PhoPQ regulation of the outer membrane to resist innate immunity Curr. Opin. Microbiol. 17 2014 106 113 10.1016/j.mib.2013.12.005
56. D. Münch, T. Roemer, S.H. Lee, M. Engeser, H.G. Sahl, and T. Schneider Identification and in vitro analysis of the GatD/MurT enzyme-complex catalyzing lipid II amidation in Staphylococcus aureus PLoS Pathog. 2012 10.1371/journal.ppat.1002509
57. S. Mahapatra, D.C. Crick, and P.J. Brennan Comparison of the UDP-Nacetylmuramate: l-alanine ligase enzymes from Mycobacterium tuberculosis and Mycobacterium leprae J. Bacteriol. 182 2000 6827 6830
58. K.H. Schleifer, and O. Kandler Peptidoglycan types of bacterial cell walls and their taxonomic implications Bacteriol. Rev. 36 1972 407 477
59. W.G. Struve, and F.C. Neuhaus Evidence for an initial acceptor of UDP-NAc-muramylpentapeptide in the synthesis of bacterial mucopeptide Biochem. Biophys. Res. Commun. 18 1965 6 12
60. M. Arthur, C. Molinas, F. Depardieu, and P. Courvalin Characterization of Tn1546, a Tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147 J. Bacteriol. 175 1993 117 127
61. M. Arthur, P. Reynolds, and P. Courvalin Glycopeptide resistance in enterococci Trends Microbiol. 4 1996 401 407
62. C.T. Walsh, S.L. Fisher, I.S. Park, M. Prahalad, and Z. Wu Bacterial resistance to vancomycin: five genes and one missing hydrogen bond tell the story Chem. Biol. 3 1996 21 28
63. T.D.H. Bugg, G.D. Wright, S. Dutka-Malen, M. Arthur, P. Courvalin, and C. Walsh Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA Biochemistry 30 1991 10408 10415
64. F. Van Bambeke Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy Curr. Opin. Investig. Drugs 7 8 2006 740 749
65. P.K. Linden Vancomycin resistance: are there better glycopeptides coming? Expert Rev. Anti Infect. Ther. 6 2008 917 928
66. F. Van Bambeke, M.P. Mingeot-Leclercq, M.J. Struelen, and P.M. Tulkens The bacterial envelope as a target for novel anti-MRSA antibiotics Trends Pharmacol. Sci. 29 2008 124 134
67. D.L. Higgins, R. Chang, D.V. Debabov, J. Leung, T. Wu, K.M. Krause, E. Sandvik, J.M. Hubbard, K. Kaniga, D.E. Schmidt Jr., Q. Gao, and et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus Antimicrob. Agents Chemother. 49 3 2005 1127 1134
68. D.C. Draghi, B.M. Benton, K.M. Krause, C. Thornsberry, C. Pillar, and D.F. Sahm Comparative surveillance study of telavancin activity against recently collected Gram-positive clinical isolates from across the United States Antimicrob. Agents Chemother. 52 7 2008 2383 2388
69. R.N. Jones, M.S. Barrett, and M.E. Erwin In vitro activity of LY333328, a novel glycopeptides derivative Antimicrob. Agents Chemother. 41 1997 488 493
70. N.E. Allen From vancomycin to oritavancin: the discovery and development of a novel lipoglycopeptide antibiotic Antiinfect. Agents Med. Chem. 9 2010 23 47
71. F.F. Arhin, D.C. Drahi, C.M. Pillar, and et al. Comparative in vitro activity profile of oritavancin against recent Gram-positive clinical isolates Antimicrob. Agents Chemother. 53 2009 4762 4771
72. C.M. Rubino, S.A. Van Wart, S.M. Bhavnani, and et al. Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia Antimicrob. Agents Chemother. 53 2009 4422 4428
73. G.J. Fetterly, C.M. Ong, S.M. Bhavnani, and et al. Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milliGram dose for 3 days or a single 800-milliGram dose Antimicrob. Agents Chemother. 49 2005 148 152
74. G.G. Zhanel, D. Calic, F. Schweizer, and et al. Dalbavancin, oritavancin and telavancin: a comparative review Drugs 70 2010 859 886
75. A. Belley, G.A. McKay, F.F. Arhin, and et al. Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing Antimicrob. Agents Chemother. 54 2010 5369 5371
76. G.A. McKay, S. Beaulieu, F.F. Arhin, and et al. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium J. Antimicrob. Chemother. 63 2009 1191 1199
77. T. Morrow One-shot staph treatment offers many advantages Manag. Care 23 2014 55 56
78. G.J. Patti, S.J. Kim, T.Y. Yu, and et al. Vancomycin and oritavancin have different modes of action in Enterococcus faecium J. Mol. Biol. 392 2009 1178 1191
79. S.J. Kim, L. Cegelski, D. Stueber, and et al. Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus J. Mol. Biol. 377 2008 281 293
80. C.A. Arias, G.A. Contreras, and B.E. Murray Management of multi-drug resistant enterococcal infections Clin. Microbiol. Infect. 16 2010 555 562
81. A.M. Stranden, K. Ehlert, H. Labischinski, and B. Berger-Bächi Cell wall monoglycine crossbridges and methicillin hypersusceptibility in a femAB null mutant of methicillin-resistant Staphylococcus aureus J. Bacteriol. 179 1997 9 16
82. S. Boyle-Vavra, H. Labischinski, C.C. Ebert, K. Ehlert, and R.S. Daum A spectrum of changes occurs in peptidoglycan composition of glycopeptide-intermediate clinical Staphylococcus aureus isolates Antimicrob. Agents Chemother. 45 2001 280 287
83. D. Gally, and A.R. Archibald Cell wall assembly in Staphylococcus aureus: proposed absence of secondary crosslinking reactions J. Gen. Microbiol. 139 1993 1907 1913
84. A. Zapun, J. Philippe, K.A. Abrahams, L. Signor, D.I. Roper, E. Breukink, and T. Vernet In vitro reconstitution of peptidoglycan assembly from the Gram-positive pathogen Streptococcus pneumoniae ACS Chem. Biol. 8 12 2013 2688 2696 10.1021/cb400575t
85. W. Vollmer, D. Blanot, and M.A. de Pedro Peptidoglycan structure and architecture FEMS Microbiol. Rev. 32 2008 149 167
86. T. Schneider, M.M. Senn, B. Berger-Bächi, A. Tossi, H.G. Sahl, and I. Wiedemann In vitro assembly of a complete, pentaglycine interpeptide bridge containing cell wall precursor (lipid II-Gly5) of Staphylococcus aureus Mol. Microbiol. 53 2004 675 685
87. A. Bouhss, N. Josseaume, A. Severin, K. Tabei, J.-E. Hugonnet, D. Shlaes, D. Mengin-Lecreulx, J. van Heijenoort, and M. Arthur Synthesis of the l-alanyl-l-alanine cross-bridge of Enterococcus faecalis peptidoglycan J. Biol. Chem. 277 2002 45935 45941
88. S.R. Filipe, E. Severina, and A. Tomasz Functional analysis of Streptococcus pneumoniae MurM reveals the region responsible for its specificity in the synthesis of branched cell wall peptides J. Biol. Chem. 276 2001 39618 39628
89. A.P. Maillard, S. Biarrotte-Sorin, R. Villet, S. Mesnage, A. Bouhss, W. Sougakoff, C. Mayer, and M. Arthur Structure-based site-directed mutagenesis of the UDP-MurNAc pentapeptide-binding cavity of the FemX alanyl-transferase from Weissella viridescens J. Bacteriol. 187 2005 3833 3838
90. S. Bellais, M. Arthur, L. Dubost, J.-E. Hugonnet, L. Gutmann, J. van Heijenoort, R. Legrand, J.-P. Brouard, L. Rice, and J.-L. Mainardi Aslfm, the d-aspartate ligase responsible for the addition of d-aspartic acid onto the peptidoglycan precursor of Enterococcus faecium J. Biol. Chem. 281 2006 11586 11594
91. P. Veiga, S. Piquet, A. Maisons, S. Furlan, P. Courtin, M.-P. Chapot-Chartier, and S. Kulakauskas Identification of an essential gene responsible for d-Asp incorporation in the Lactococcus lactis peptidoglycan crossbridge Mol. Microbiol. 62 2006 1713 1724
92. W. Staudenbauer, and J.L. Strominger Activation of d-aspartic acid for incorporation into peptidoglycan J. Biol. Chem. 247 1972 5095 5102
93. S.S. Hegde, and T.E. Shrader FemABX family members are novel nonribosomal peptidyltransferases and important pathogen-specific drug targets J. Biol. Chem. 276 2001 6998 7003
94. B.P. Howden, J.K. Davies, P.D.R. Johnson, T.P. Stinear, and M.L. Grayson Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications 23 2010 99 139
95. A. Severin, K. Tabei, F. Tenover, M. Chung, N. Clarke, and A. Tomasz High level Oxacillin and vancomycin resistance and altered cell wall composition in Staphylococcus aureus carrying the staphylococcal mecA and the enterococcal vanA gene complex J. Biol. Chem. 279 2004 3398 3407
96. A. Severin, S.W. Wu, K. Tabei, and A. Tomasz Penicillin-binding protein 2 is essential for expression of high-level vancomycin resistance and cell wall synthesis in vancomycin-resistant Staphylococcus aureus carrying the vanA gene complex Antimicrob. Agents Chemother. 48 2004 4566 4573
97. N. Koyama, Y. Tokura, D. Münch, H.G. Sahl, T. Schneider, Y. Shibagaki, H. Ikeda, and H. Tomoda The nonantibiotic small molecule cyslabdan enhances the potency of β-lactams against MRSA by inhibiting pentaglycineinterpeptide bridge, synthesis PLoS One 7 2012 e48981
98. D. Münch, I. Engels, A. Müller, K. Reder-Christ, H. Falkenstein-Paul, G. Bierbaum, F. Grein, G. Bendas, H.G. Sahl, and T. Schneider Structural variations of the cell wall precursor lipid II - influence on binding and activity of the lipoglycopeptide antibiotic oritavancin Antimicrob. Agents Chemother. 59 2 2015 772 781 10.1128/AAC.02663-14
99. G. Siewert, and J.L. Strominger Biosynthesis of the peptidoglycan of bacterial cell walls. XI. Formation of the isoglutamine amide group in the cell walls of Staphylococcus aureus J. Biol. Chem. 243 1968 783 790
100. J. Gustafson, A. Strassle, H. Hachler, F.H. Kayser, and B. Berger-Bächi The femC locus of Staphylococcus aureus required for methicillin resistance includes the glutamine synthetase operon J. Bacteriol. 176 1994 1460 1467
101. A.M. Stranden, M. Roos, and B. Berger-Bächi Glutamine synthetase and heteroresistance in methicillin-resistant Staphylococcus aureus Microb. Drug Resist. 2 1996 201 207
102. M. Nakel, J.M. Ghuysen, and O. Kandler Wall peptidoglycan in Aerococcus viridans strains 201 Evans and ATCC 11563 and in Gaffkya homari strain ATCC 10400 Biochemistry 10 1971 2170 2175
103. T.A. Figueiredo, R.G. Sobral, A.M. Ludovice, J.M. de Almeida, N.K. Bui, W. Vollmer, H. de Lencastre, and A. Tomasz Identification of genetic determinants and enzymes involved with the amidation of glutamic acid residues in the peptidoglycan of Staphylococcus aureus PLoS Pathog. 8 1 2012 e1002508
104. H. Hanaki, H. Labischinski, Y. Inaba, N. Kondo, H. Murakami, and K. Hiramatsu Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50 J. Antimicrob. Chemother. 42 1998 315 320
105. I.G. Boneca The role of peptidoglycan in pathogenesis Curr. Opin. Microbiol. 8 2005 46 53
106. M.A. Wolfert, A. Roychowdhury, and G.J. Boons Modification of the structure of peptidoglycan is a strategy to avoid detection by nucleotide-binding oligomerization domain protein 1 Infect. Immun. 75 2007 706 713
107. S. Herbert, A. Bera, C. Nerz, D. Kraus, A. Peschel, and et al. Molecular basis of resistance to muramidase and cationic antimicrobial peptide activity of lysozyme in staphylococci PLoS Pathog. 3 2007 e102
108. K. Amano, H. Hayashi, Y. Araki, and E. Ito The action of lysozyme on peptidoglycan with N-unsubstituted glucosamine residues. Isolation of glycan fragments and their susceptibility to lysozyme Eur. J. Biochem. 76 1977 299 307
109. W. Vollmer Structural variation in the glycan strands of bacterial peptidoglycan FEMS Microbiol. Rev. 32 2008 287 306
110. K.M. Davis, and J.N. Weiser Modifications to the peptidoglycan backbone help bacteria to establish infection Infect. Immun. 79 2 2011 562 570
111. A. Bera, R. Biswas, S. Herbert, and F. Götz The presence of peptidoglycan O-acetyltransferase in various staphylococcal species correlates with lysozyme resistance and pathogenicity Infect. Immun. 74 2006 4598 4604
112. A. Bera, R. Biswas, S. Herbert, E. Kulauzovic, C. Weidenmaier, and et al. Influence of wall teichoic acid on lysozyme resistance in Staphylococcus aureus J. Bacteriol. 189 2007 280 283
113. T. Shimada, and et al. Staphylococcus aureus evades lysozyme-based peptidoglycan digestion that links phagocytosis, inflammasome activation, and IL-1β secretion Cell Host Microbe 7 2010 38 49
114. M. Crisóstomo, and et al. Attenuation of penicillin resistance in a peptidoglycan O-acetyl transferase mutant of Streptococcus pneumoniae Mol. Microbiol. 61 2006 1497 1509
115. L. Hébert, P. Courtin, R. Torelli, M. Sanguinetti, and M. Chapot-Chartier Enterococcus faecalis constitutes an unusual bacterial model in lysozyme resistance Infect. Immun. 75 2007 5390 5398
116. P. Veiga, and et al. SpxB regulates O-acetylation-dependent resistance of Lactococcus lactis peptidoglycan to hydrolysis J. Biol. Chem. 282 2007 19342 19354
117. J. Dillard, and K. Hackett Mutations affecting peptidoglycan acetylation in Neisseria gonorrhoeae and Neisseria meningitidis Infect. Immun. 73 2005 5697 5705
118. W. Vollmer, and A. Tomasz The pgdA gene encodes for a peptidoglycan N-acetylglucosamine deacetylase in Streptococcus pneumoniae J. Biol. Chem. 275 2000 20496 20501
119. W. Vollmer, and A. Tomasz Peptidoglycan N-acetylglucosamine deacetylase, a putative virulence factor in Streptococcus pneumoniae Infect. Immun. 70 2002 7176 7178
120. I. Boneca, and et al. A critical role for peptidoglycan N-deacetylation in Listeria evasion from the host innate immune system Proc. Natl. Acad. Sci. U. S. A. 104 2007 997 1002
121. G. Wang, A. Olczak, L. Forsberg, and R. Maier Oxidative stress-induced peptidoglycan deacetylase in Helicobacter pylori J. Biol. Chem. 284 2009 6790 6800
122. A. Peschel, and H.-G. Sahl The co-evolution of host cationic antimicrobial peptides and microbial resistance Nat. Rev. Microbiol. 4 2006 529 536